Plain-English translation of NCT06758713 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Multiple Myeloma research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This clinical trial is testing a new type of immunotherapy called fourth-generation cell therapy for treating blood cancers like multiple myeloma and lymphoma. Researchers are studying whether this treatment is safe and how well it works by giving patients different doses of specially engineered immune cells. The goal is to find the best dose and understand what side effects patients might experience.
Current treatments for blood cancers don't work for everyone, and some patients relapse or don't respond well. This medication uses a newer generation of engineered immune cells designed to be more effective and potentially safer than earlier versions.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
Before receiving the treatment, you will receive chemotherapy to prepare your body. Then you will receive an infusion of the engineered immune cells (the dose will depend on which group you're assigned to). After infusion, you will be closely monitored for side effects and how well the treatment is working. The trial involves multiple follow-up visits to check your blood work, heart function, and overall health.
AI-generated summary from trial data ยท Jun 10, 2026 ยท Not medical advice
China